AUS
NZ
UK
CA
USA
IND
Highlights:
- Successful Subject Enrolment: Island Pharmaceuticals Ltd (ASX:ILA) has commenced its Phase 2b clinical trial for ISLA-101, enrolling the first subjects to assess the drug's therapeutic potential against dengue fever.
- Focus on Treatment Efficacy: Phase 2b aims to evaluate ISLA-101's ability to reduce viremia and alleviate dengue symptoms, building on promising Phase 2a results showing safety and antiviral activity.
- Progressive Momentum: Four participants have been enrolled, with the remaining six expected shortly, continuing the program's steady progression.
Island Pharmaceuticals Ltd (ASX:ILA) has successfully initiated its Phase 2b clinical trial to evaluate ISLA-101, a drug designed to combat dengue fever. This trial marks a significant step in the drug's development, targeting both safety and therapeutic efficacy in infected individuals.
Following the successful completion of the Phase 2a trial, which demonstrated ISLA-101's safety and anti-dengue activity, the Safety Review Committee (SRC) recommended progressing to the Phase 2b stage. This trial shifts focus from prevention to treatment, expanding on prior findings that highlighted the drug's antiviral capabilities.
The Phase 2b study involves 10 participants, randomized in an 8:2 ratio between ISLA-101 and a placebo. Currently, four participants have been enrolled, with the remaining six expected to join within the next two weeks. Participants are exposed to a weakened strain of the dengue virus and then receive either the placebo or ISLA-101 seven days later.
The trial's primary endpoint is to assess the drug's impact on viremia—reducing the viral load in the bloodstream. Secondary goals include confirming the safety of ISLA-101 and evaluating its ability to alleviate the symptoms of dengue fever.
Dr. David Foster, CEO and Managing Director of Island Pharmaceuticals, emphasized the importance of the trial's timely progression. He highlighted the SRC’s landmark conclusion during the Phase 2a trial, which revealed evidence of antiviral activity in a prophylactic setting. The current study aims to determine whether ISLA-101 exhibits similar efficacy as a therapeutic option for dengue-infected individuals.
Dr. Foster remarked on the significant strides made over the past year, noting the program's achievements in exploring ISLA-101 as a potential dengue treatment. He expressed optimism about the ongoing momentum and the potential of this drug to address a pressing global health challenge.
The advancement of ISLA-101 into Phase 2b underscores Island Pharmaceuticals' commitment to addressing the unmet medical needs posed by dengue fever. With millions affected annually by the disease, an effective treatment could have substantial global health implications.
Island Pharmaceuticals continues to progress its clinical program with rigorous scientific evaluation, aiming to develop ISLA-101 as a safe and effective therapeutic solution for dengue fever.
